BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
327.01
-13.37 (-3.93%)
Feb 2, 2026, 8:02 AM EST - Market open
BeOne Medicines AG Employees
BeOne Medicines AG had 11,000 employees as of September 30, 2025. The number of employees increased by 1,000 or 10.00% compared to the same quarter last year.
Employees
11,000
Change
1,000
Growth
10.00%
Revenue / Employee
$452,062
Profits / Employee
$6,232
Market Cap
36.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | 8,000 | 2,700 | 50.94% | 8,000 | 0 |
| Sep 30, 2021 | 7,600 | 3,000 | 65.22% | 7,600 | 0 |
| Mar 31, 2021 | 5,400 | 1,800 | 50.00% | 5,400 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,106 |
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Alnylam Pharmaceuticals | 2,230 |
| argenx SE | 1,599 |
| Insmed | 1,271 |
ONC News
- 19 days ago - BeOne Medicines AG (ONC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 26 days ago - ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA - Business Wire
- 5 weeks ago - BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma - Business Wire
- 7 weeks ago - Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors - PRNewsWire
- 2 months ago - BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia - Business Wire
- 2 months ago - Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies - Business Wire